Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24671538 | 0.84 | MAPT (0.58) | MAPTMEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL2682582 | 0.84 | ABL1 (0.53) | MAPTMEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL2681972 | 0.82 | RAB9A (0.63) | MAPTMEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL9996831 | 0.76 | MAPT (0.51) | MAPTMEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL4727649 | 0.76 | KCNQ3 (0.58) | MAPTMEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL527474 | 0.76 | TDP1 (0.65) | MAPTMEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL16560420 | 0.74 | TBK1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL4257363 | 0.72 | NPC1 (0.65) | MAPTMEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL2055269 | 0.71 | RAB9A (0.67) | KMT2ANPC1SMN1; SMN2TP53KDM4E | |
| SCHEMBL29803730 | 0.70 | GRM4 (0.56) | MAPTMEN1KMT2AKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2635571-B1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8921372-B2 | Inhibitors of hepatitis C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2635571-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | Theravance, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061552-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | MAPT 3876/4885MEN1 3635/4885KMT2A 4426/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | MAPT 4309/4885MEN1 4415/4885KMT2A 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.